Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of “Hold” from Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have earned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $51.75.

A number of brokerages have recently weighed in on PSTV. Ascendiant Capital Markets cut their price objective on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th.

Plus Therapeutics Price Performance

Shares of PSTV opened at $3.02 on Friday. The firm has a market capitalization of $20.79 million, a PE ratio of -1.31 and a beta of 1.40. Plus Therapeutics has a 1-year low of $2.90 and a 1-year high of $23.42. The company’s fifty day moving average price is $3.79 and its 200-day moving average price is $5.25.

Plus Therapeutics (NASDAQ:PSTV) last issued its earnings results on Thursday, August 13th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.43). Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.The firm had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $1.11 million. As a group, research analysts anticipate that Plus Therapeutics will post -3.76 EPS for the current fiscal year.

Institutional Trading of Plus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in shares of Plus Therapeutics in the 2nd quarter valued at $41,000. Susquehanna International Group LLP acquired a new position in Plus Therapeutics during the third quarter valued at $46,000. Scientech Research LLC acquired a new position in Plus Therapeutics during the third quarter valued at $100,000. XTX Topco Ltd purchased a new stake in Plus Therapeutics in the fourth quarter valued at $127,000. Finally, State Street Corp boosted its holdings in Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after purchasing an additional 127,000 shares during the last quarter. 3.28% of the stock is currently owned by institutional investors and hedge funds.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.